Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

December 5, 2014

Oncologists examine efficacy of rose bengal against cancer

A News Medical article discusses PV-10 clinical studies, as well as recent murine melanoma studies combining PV-10 and co-inhibitory blockade, and the recent surge in attention being given to combination therapies by both big pharma and the media.

December 5, 2014

Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment

An article appearing on Melanoma News Today reports that during the 29th annual meeting of the Society for Immunotherapy of Cancer, Dr. Shari Pilon-Thomas of the Moffitt Cancer Center, presented a study titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma" revealing new results that encourage the combination of PV-10 and co-inhibitory blockade drugs for the treatment of melanoma.

December 4, 2014

Rose Bengal and Co-Inhibitory Blockade Improve Anti-Tumor Immunity, Melanoma Regression

An article appearing on Practical Dermatology's dermwire reports on data presented at the 29th annual meeting of the Society for Immunotherapy of Cancer by a team from Moffitt Cancer showing that IL PV-10 and co-inhibitory blockade could improve anti-tumor immunity and regression of melanoma in mice.

December 2, 2014

PV-10 Data Published; Phase 3 Protocol Published

An article appearing on Practical Dermatology's dermwire reports that Phase 2 PV-10 data were recently published in Annals of Surgical Oncology and that the protocol for a Phase 3 Study of PV-10 as a treatment for melanoma was published at clinicaltrials.gov.

November 20, 2014

PV-10 and checkpoint inhibitor enhance melanoma regression

An article appearing on Pharmiweb reports that data from a murine study combining PV-10 with checkpoint inhibitors (anti-CTLA, and second generation immune check point inhibitors anti-PD-1 and anti-PD-L1) show that mice injected with PV-10 and anti-PD-L1 had significant delays in tumour growth compared with mice injected with PBS + NrlgG; PBS + anti-PD-L1; or PV-10 + NrlgG. Furthermore T cells isolated from spleens of mice injected with both PV-10 and anti-PD-L1 produced significantly more interferon gamma (a surrogate for T cell reactivity) compared to the other three groups.

November 19, 2014

Combination of PV-10 and checkpoint inhibitor boosts melanoma tumour regression

An article appearing on ecancer reports on an investigation of PV-10 in combination with anti-CTLA, and the second generation immune check point inhibitors anti-PD-1 and anti-PD-L1. Data from the murine study was recently presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting by Moffitt Cancer Center researchers.

November 18, 2014

Melanoma shows improved regression with combination of PV-10 and checkpoint inhibitor

An article appearing on Medical News Today reports on data presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting showing that combination therapy of intralesional (IL) PV-10 and anti-PD-L1 antibodies enhanced regression of "bystander" (uninjected lesions) in comparison to either treatment used alone.

November 17, 2014

Provectus Biopharmaceuticals Presents PV-10 Data

An article appearing in Pharmacy Choice reports on data presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting supporting combination therapy with IL PV-10 and co-inhibitory blockade.

November 17, 2014

It may just be do or dye time for cancer biotechs

An article appearing in The Australian reports on investigation drug PV-10 and its promising clinical results.

November 14, 2014

Eye-dye melanoma try: Provectus phase III plan for injectable with FDA

An article appearing in BioWorld reports on Provectus proposed phase 3 trial of PV-10 for locally advanced cutaneous melanoma. The protocol for the phase 3 trial was recently submitted to the FDA.

November 12, 2014

Provectus Biopharmaceuticals Issues PV-10 Phase 3 Melanoma Protocol to FDA

An article appearing in Pharmacy Choice reports that Provectus has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA and that few, if any, significant issues are anticipated to arise from review of the protocol.

November 10, 2014

Oncology News Reports on Melanoma Research Presented at ESMO

An article appearing in the November/Decembe 2014 issue of Oncology News reports on mlenaoma research presented at the 2014 European Society of Medical Oncology 2014 Congress, including a presentation showing that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

November 6, 2014

Webcast: Conference Call November 6, 2014 4:00 PM EDT

Provectus management will host its quarterly conference call on Thursday, November 6, 2014 at 4:00 PM EST.

November 3, 2014

PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3

In an article appearing on Medscape, author Walter Alexander reports that PV-10 injected directly into skin lesions, has shown rapid complete responses in a high proportion of melanoma patients in early clinical trials and discusses phase 3 study plans.

November 3, 2014

Investigational Agent For Metastatic Melanoma Shows Rapid Complete Responses In High Proportion Of Patients In Early Trials

An article appearing ASCO Cancer in the News daily digest reports on data recently published in the Annals of Oncology showing that intralesional PV-10 leads to rapid complete responses in a high proportion of patients in a phase 2 trial.

October 30, 2014

A New Cancer Drug Worked In Over 50% Of Patients In A Phase II Trial

In an article appearing on Forbes, Jon Fortenbury discusses the PV-10 phase 2 study results recently published in the journal Annals of Surgical Oncology showing that 51% of patients had an objective response with 26% having a complete reponse, and that for the 28 patients who had all of their disease treated, 50% ended the 16-week treatment period with no sign of disease.

October 22, 2014

Provectus Lists Partnering Opportunities for PV-10 and PH-10

P&T TV has posted two videos from coverage of the American Society of Clinical Oncology (ASCO) 2014 annual meeting. In these videos, titled "Intralesional Therapies Gain Recognition for Melanoma Treatment" and ""Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma", Dr. Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, discusses the promising role of intralesional therapies for melanoma and the "very impressive data" from the phase 2 trial of PV-10.

October 21, 2014

"Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma

P&T TV has posted two videos from coverage of the American Society of Clinical Oncology (ASCO) 2014 annual meeting. In these videos, titled "Intralesional Therapies Gain Recognition for Melanoma Treatment" and ""Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma", Dr. Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, discusses the promising role of intralesional therapies for melanoma and the "very impressive data" from the phase 2 trial of PV-10.

October 20, 2014

Current Perspectives on Intralesional Therapies

Dr. Sanjiv Agarwala of St. Luke's Cancer Center presented data on investigational new drug PV-10 for the treatment of melanoma on Saturday October 18 at the 2014 Beijing International Melanoma Congress. The presentation titled "Current Perspectives on Intralesional Therapies" was an abbreviated version of the presentation that Dr. Agarwala gave at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 19, 2014

Pink is the Color for Breast Cancer Cure

In a radio interview airing on eHealth Radio, Peter Culpepper, COO and CFO of Provectus Biopharmaceuticals discusses the progress of Provectus' investigational drug PV-10 in clinical trials for breast and skin cancers and how patients can find more information about clinical trials.

more...

PRESS RELEASES

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

November 14, 2014

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.

November 13, 2014

Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online

Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.

November 10, 2014

Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting

Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.

November 6, 2014

Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results

Provectus today announced financial results for the third quarter of 2014.

November 6, 2014

Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.

November 6, 2014

Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting

Provectus announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120.

November 6, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time

Provectus will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

October 15, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

Provectus announced today that Shari Pilon-Thomas, Ph.D. from the Moffitt Cancer Center will present the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting in two time slots on Saturday, November 8: 12:30 pm - 2:00 pm and 6:00 pm - 7:30 pm.

October 14, 2014

INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals

Provectus announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

October 8, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology

Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's Cancer Center will present data on its investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 7, 2014

Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress

Provectus announced today that clinical data on its investigative new drug PV-10 for the treatment of melanoma will be presented at the 2014 Beijing International Melanoma Congress. The presentation by Dr. Sanjiv Agarwala of the St. Luke's Cancer Center is titled "Current Perspectives on Intralesional Therapies." It is scheduled for 5:30 pm local time, on Saturday, October 18, 2014.

September 29, 2014

Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma was featured in a poster presentation on Sunday, September 28, 2014 during the European Society For Medical Oncology 2014 Congress in Madrid, Spain. The presentation showed that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

September 24, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at
https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.

September 23, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting with an abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma."

September 22, 2014

Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it has appointed Christopher Kaplan to its Strategic Advisory Board effective immediately.

August 18, 2014

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it entered into a Memorandum of Understanding ("MOU") with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

more...